Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Depression: Overview01:18

Depression: Overview

1.2K
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
1.2K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

2.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.1K
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

972
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
972
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

699
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
699
Drug Therapy01:28

Drug Therapy

445
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
445

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fidelity in the context of adapting a digital intervention for depression from an evidence-based in-person format in Vietnam.

BMC health services research·2026
Same author

App-Based Physical Activity Intervention for Individuals With Depression (MoodMover): Single-Arm, Pre-Post Proof-of-Concept and Feasibility Study.

JMIR formative research·2026
Same author

Youth peer-based mental health programmes and supports in low- and middle-income countries: rapid review.

BJPsych open·2026
Same author

The association between body mass index and treatment outcomes in major depressive disorder: a CAN-BIND-1 study.

Journal of psychiatric research·2026
Same author

Lam Employment Absence and Productivity Scale (LEAPS): Analysis of the minimal clinically important difference (MCID) in patients with major depressive disorder using data from the CAN-BIND-1 study.

Journal of affective disorders·2026
Same author

One-Year Actigraphy Study of Sleep and Rest-Activity Rhythms as Markers of Relapse in Depression.

JAMA psychiatry·2026
Same journal

Biological and social rhythm differences, daily melatonin secretion and psychiatric symptoms in healthy adults.

International journal of psychiatry in clinical practice·2026
Same journal

Diagnostic utility of pan-immune inflammation value in drug-naïve first-episode psychosis.

International journal of psychiatry in clinical practice·2026
Same journal

Examining neuroretinal alterations in autism spectrum disorder: a systematic review of OCT and OCT-A studies.

International journal of psychiatry in clinical practice·2026
Same journal

Depressive symptoms in patients with schizophrenia spectrum disorders and the impact on treatment motivation and satisfaction.

International journal of psychiatry in clinical practice·2026
Same journal

Predictors of premature treatment termination in an inpatient programme for women with PTSD and/or eating disorders.

International journal of psychiatry in clinical practice·2026
Same journal

Evaluation of haematological parameters in patients with first-episode psychosis: distinctions between bipolar disorder and schizophrenia spectrum disorders.

International journal of psychiatry in clinical practice·2026
See all related articles

Related Experiment Video

Updated: Apr 28, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

31.9K

Priorities in treating depression only.

Raymond W Lam1

  • 1University of British Colombia, British Columbia, Canada.

International Journal of Psychiatry in Clinical Practice
|June 17, 2014
PubMed
Summary
This summary is machine-generated.

Newer antidepressants like escitalopram offer better symptom relief and remission rates for depression compared to older SSRIs and venlafaxine. Escitalopram demonstrates faster sustained remission and improved tolerability, addressing the need for more effective depression treatments.

Keywords:
escitalopramremissionresponseselective serotonin reuptake inhibitorserotonin noradrenaline reuptake inhibitorvenlafaxine

More Related Videos

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

743
Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:54

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

1.1K

Related Experiment Videos

Last Updated: Apr 28, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

31.9K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

743
Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:54

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

1.1K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Physician dissatisfaction with current depression treatments highlights the need for therapies with rapid symptom relief, high remission rates, and recurrence prevention.
  • Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) show higher remission rates than other antidepressants.
  • Venlafaxine, an SNRI, has demonstrated higher remission rates than some SSRIs in meta-analyses.

Purpose of the Study:

  • To compare the efficacy and tolerability of newer selective serotonin reuptake inhibitors (SSRIs) with older SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs).
  • Specifically, to evaluate escitalopram against citalopram and extended-release venlafaxine in treating depression.

Main Methods:

  • Pooled data from three studies were used for analysis.
  • Escitalopram was compared to citalopram and placebo for responder rates (≥50% decrease in Montgomery and Åsberg Depression Rating Scale [MADRS] score).
  • Flexible-dose studies compared escitalopram and extended-release venlafaxine for remission rates (MADRS ≤12) and time to sustained remission.

Main Results:

  • Escitalopram showed significantly higher responder rates than citalopram and placebo.
  • In an 8-week flexible-dose study, escitalopram achieved higher remission rates than citalopram.
  • Escitalopram and venlafaxine had similar overall remission rates, but escitalopram led to sustained remission nearly a week earlier.
  • Escitalopram demonstrated higher remission rates in severely ill patients and offered better tolerability compared to venlafaxine.

Conclusions:

  • Escitalopram is a highly effective treatment for depression, demonstrating superior efficacy over citalopram and comparable, yet faster-acting, remission rates to venlafaxine.
  • Escitalopram offers significant advantages in tolerability over venlafaxine.
  • The findings support escitalopram as an improved therapeutic option for depression, meeting the demand for rapid symptom relief and high remission rates.